BCL2 and neoplasm: This assumption is largely supported by Shahbandi et al.’s observations where certain doxorubicin-induced tumor cell lines were not initially sensitive to navitoclax and required further interference with other BCL-2 family members—namely, the concomitant inhibition of MCL-1, while other cell lines exposed to the same stimulus were readily susceptible to senolysis by navitoclax [116].